Institute for Molecular Medicine Finland, Helsinki Institute of Life Science HiLIFE, INDIVIDRUG - Individualized Drug Therapy, Department of Clinical Pharmacology, Clinicum, HUS Psychiatry, Department of Psychiatry, Genomics of Neurological and Neuropsychiatric Disorders, Department of Psychology and Logopedics, HYKS erva, HUS Perioperative, Intensive Care and Pain Medicine, Department of Diagnostics and Therapeutics, Anestesiologian yksikkö, HUSLAB, Medicum, HUS Diagnostic Center, Centre of Excellence in Complex Disease Genetics, Research Programs Unit, Tampere University, Health Sciences, Clinical Medicine, Department of Psychotic Disorders
We demonstrate that CYP2D6 copy-number variation (CNV) can be imputed using existing imputation algorithms. Additionally, we report frequencies of key pharmacogenetic variants in individuals with a psychotic disorder from the genetically bottle-necked population of Finland. We combined GWAS chip and CYP2D6 CNV data from the Breast Cancer Pain Genetics study to construct an imputation panel (n = 902) for CYP2D6 CNV. The resulting data set was used as a CYP2D6 CNV imputation panel in 9262 non-related individuals from the SUPER-Finland study. Based on imputation of 9262 individuals we confirm the higher frequency of CYP2D6 ultrarapid metabolizers and a 22-fold enrichment of the UGT1A1 decreased function variant rs4148323 (UGT1A1*6) in Finland compared with non-Finnish Europeans. Similarly, the NUDT15 variant rs116855232 was highly enriched in Finland. We demonstrate that imputation of CYP2D6 CNV is possible and the methodology enables studying CYP2D6 in large biobanks with genome-wide data.
